CAR-T cells in the treatment of neurological autoimmune diseases
Vonberg FW., Schroeder BE., Edwards A., Sun B., Keh RY., Ashraghi MR., Joe D., Gorgoraptis N., Rees J., Davies NWS., Finnerty G., Willis M., Leite MI., Gold R., Motte J., Carr AS., Keddie S.
Chimeric antigen receptor T cells (CAR-T cells) have revolutionised cancer treatment by offering personalised therapy of unprecedented efficacy to patients with relapsed B-cell malignancies and myeloma. CAR-T cells are designed selectively to target CD19 or other B-cell antigens with high affinity, leading to a potent immune response and effective killing of malignant B cells. More recently, CAR-T treatment has been shown to be safe and effective in a very limited number of patients with severe, refractory autoimmune conditions such as systemic lupus erythematosus, systemic sclerosis and myositis. This paper describes the early use and feasibility of CAR-T therapies in the treatment of refractory autoimmune neurological diseases.